About
The intricate scaffolding of contemporary economies is significantly upheld by capital markets, which furnish the requisite funds enabling businesses to evolve, expand, and generate employment opportunities. Within this context, synthetic biology is an especially capital-reliant sector, necessitating substantial initial investments facilitated predominantly through venture capital. External market dynamics, however, introduce potential vulnerabilities, especially in the maturation phase of synbio enterprises. Conversely, nascent startups face the imperative of robust differentiation and intellectual property safeguarding to secure pivotal funding. For visionaries in synthetic biology, adept navigation of the investment topography is paramount. It becomes quintessential for such entrepreneurs to be well-versed in the multifaceted avenues and intricacies of capital acquisition to burgeon their ventures.
Speakers
Agenda
Agenda
Monday
May 05
Tuesday
May 06
Wednesday
May 07
Scaling SynBio: Investment Strategies from Lab to Market
-
Transitioning synthetic biology innovations from the lab to commercial scale requires strategic investment, robust infrastructure, and cross-sector collaboration. This session explores the financial and operational challenges of scaling the bioeconomy in the UK and Europe, highlighting key funding mechanisms, investor perspectives, and case studies of successful scale-ups. Join this session to understand the investment landscape, technology readiness, and market adoption and hear insights for startups and stakeholders looking to bridge the gap between research and commercialization.
Innovation Meets Industry: How Startups Can Collaborate with Big Pharma
-
For startups in the BioPharma space, partnering with big pharma can be the key to scaling innovation and driving real-world impact. This session will bring together leaders from major pharmaceutical companies and successful startups to explore how to bridge the gap between groundbreaking ideas and industry execution. Learn about the key factors pharma companies look for in potential partners, best practices for collaboration" with "Innovation Meets Industry: How Startups Can Collaborate with Big Pharma"
Disrupt, Discover, Deliver: The New Wave of Tech Bio Investments
-
Explore how emerging tech bio ventures are reshaping traditional market dynamics and capturing the attention of forward-thinking investors. This session dives into key trends in synthetic biology, computational life sciences, and platform-based drug discovery, highlighting strategies to accelerate breakthroughs and unlock value at scale. Hear seasoned venture experts discuss the evolving regulatory and investment landscapes, share approaches to building high-growth portfolios, and provide insights on nurturing disruptive companies from seed to maturity. Join a candid dialogue on how collaboration, cutting-edge research, and risk management converge to drive the future of tech bio innovation.
Entrepreneurial Excellence in BioPharma: Lessons from the Frontlines
-
Join a panel of pioneering BioPharma entrepreneurs as they share their hard-earned lessons and experiences from building successful ventures in one of the most challenging and dynamic industries. This session will explore key strategies for overcoming regulatory hurdles, securing funding, navigating partnerships, and driving biopharma innovation from the lab to the marketplace.
Thursday
May 08
Risk, Resilience & Returns: New Frameworks for SynBio Investment
-
Bringing together leaders in synthetic biology and finance, this session scrutinizes new methods for balancing uncertainty, sustaining resilience, and optimizing returns in a field characterized by rapid innovation and protracted development timelines. Panelists will examine strategies for portfolio diversification across pivotal subfields—ranging from biomaterials to industrial fermentation—while highlighting the vital role of thorough scientific diligence and regulatory insight. By emphasizing the synergy between rigorous research and principled investment approaches, this discussion offers a timely examination of how careful planning can guide groundbreaking discoveries from the laboratory into sustained commercial success.
Infrastructure Investments for Accelerating the Bioeconomy
-
In this session, we'll discuss the pivotal role of infrastructure investments in accelerating the bioeconomy. Harnessing the full potential of synthetic biology requires access to expensive infrastructure for biomanufacturing and scale-up. We'll dive into how investors, CMOs, and startups are capitalizing on this opportunity space to accelerate bringing products to market.
Conference Pass
2,495
USD
Keynotes & Firesides
Workshops & Breakouts
1:1 Partnering App
Meals & Receptions
Session Recordings
Until Friday April 18th
Full Rate:
$3,495
